Abstract
Background - Progressive pulmonary dysfunction is a characteristic symptom of cystic fibrosis (CF) and is associated with functional impairment and biochemical alterations of surfactant phospholipids in the airways. However, the fundamental question of whether surfactant alterations in the CF lung are secondary to the pulmonary damage or are present before initiation of chronic infection and inflammation has yet to be resolved in patients with cystic fibrosis but can now be addressed in CF mice that exhibit the basic defect in the airways. A study was therefore undertaken to investigate the pool sizes, composition, and function of lung surfactant in the non-infected cftr(m1HGU/m1HGU) mouse. Methods - The amount and composition of phospholipid classes and phosphatidylcholine molecular species were determined in bronchoalveolar lavage (BAL) fluid and lavaged lungs by high performance liquid chromatography (HPLC). Surfactant protein A (SP-A) levels in BAL fluid were determined by ELISA and surfactant for functional measurements was isolated from BAL fluid by differential ultracentrifugation. Equilibrium and minimal surface tension of surfactant was assessed by the pulsating bubble surfactometer technique. MF1, BALB/c, C57/BL6, and C3H/He mice served as controls. Results - BAL fluid of cftr(m1HGU/m1HGU) mice contained 1.02 (95% confidence interval (CI) 0.89 to 1.16) μmol phospholipid and 259 (239 to 279) ng SP-A. BAL fluid of MF1, BALB/c, C57BL/6, and G3H/He mice contained 0.69 (0.63 to 0.75), 0.50 (0.42 to 0.57), 0.52 (0.40 to 0.64), and 0.45 (0.27 to 0.63) μmol phospholipid, respectively. After correction for the different body weights of mouse strains, phospholipid levels in BAL fluid of cftr(mlHGU/mlHGU) mice were increased by 64 (52 to 76)%, 60 (39 to 89)%, 72 (45 to 113)%, and 92 (49 to 163)%, respectively, compared with controls. The amount of SP-A in BAL fluid and the composition of phospholipid as well as phosphatidylcholine molecular species in BAL fluid and lung tissue was unchanged in 1HGU/m1HGU mice compared with controls. The increase in phospholipids in BAL fluid of cftr(m1HGU/m1HGU) mice resulted from an increased fraction of large aggregates which exhibited normal surface tension function. Conclusion - In cftr(m1HGU/m1HGU) mice surfactant homeostasis is perturbed by an increased phospholipid pool in the alveolar compartment.
| Original language | English |
|---|---|
| Pages (from-to) | 723-730 |
| Number of pages | 8 |
| Journal | Thorax |
| Volume | 52 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1997 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
Cite this
}
Lung surfactant in a cystic fibrosis animal model : Increased alveolar phospholipid pool size without altered composition and surface tension function in cftr(m1HGU/m1HGU) mice. / Bernhard, Wolfgang; Wang, Jiu-Yao; Tschernig, Thomas; Tümmler, Burkhard; Hedrich, Hans J.; Von Der Hardt, Horst.
In: Thorax, Vol. 52, No. 8, 01.01.1997, p. 723-730.Research output: Contribution to journal › Article
TY - JOUR
T1 - Lung surfactant in a cystic fibrosis animal model
T2 - Increased alveolar phospholipid pool size without altered composition and surface tension function in cftr(m1HGU/m1HGU) mice
AU - Bernhard, Wolfgang
AU - Wang, Jiu-Yao
AU - Tschernig, Thomas
AU - Tümmler, Burkhard
AU - Hedrich, Hans J.
AU - Von Der Hardt, Horst
PY - 1997/1/1
Y1 - 1997/1/1
N2 - Background - Progressive pulmonary dysfunction is a characteristic symptom of cystic fibrosis (CF) and is associated with functional impairment and biochemical alterations of surfactant phospholipids in the airways. However, the fundamental question of whether surfactant alterations in the CF lung are secondary to the pulmonary damage or are present before initiation of chronic infection and inflammation has yet to be resolved in patients with cystic fibrosis but can now be addressed in CF mice that exhibit the basic defect in the airways. A study was therefore undertaken to investigate the pool sizes, composition, and function of lung surfactant in the non-infected cftr(m1HGU/m1HGU) mouse. Methods - The amount and composition of phospholipid classes and phosphatidylcholine molecular species were determined in bronchoalveolar lavage (BAL) fluid and lavaged lungs by high performance liquid chromatography (HPLC). Surfactant protein A (SP-A) levels in BAL fluid were determined by ELISA and surfactant for functional measurements was isolated from BAL fluid by differential ultracentrifugation. Equilibrium and minimal surface tension of surfactant was assessed by the pulsating bubble surfactometer technique. MF1, BALB/c, C57/BL6, and C3H/He mice served as controls. Results - BAL fluid of cftr(m1HGU/m1HGU) mice contained 1.02 (95% confidence interval (CI) 0.89 to 1.16) μmol phospholipid and 259 (239 to 279) ng SP-A. BAL fluid of MF1, BALB/c, C57BL/6, and G3H/He mice contained 0.69 (0.63 to 0.75), 0.50 (0.42 to 0.57), 0.52 (0.40 to 0.64), and 0.45 (0.27 to 0.63) μmol phospholipid, respectively. After correction for the different body weights of mouse strains, phospholipid levels in BAL fluid of cftr(mlHGU/mlHGU) mice were increased by 64 (52 to 76)%, 60 (39 to 89)%, 72 (45 to 113)%, and 92 (49 to 163)%, respectively, compared with controls. The amount of SP-A in BAL fluid and the composition of phospholipid as well as phosphatidylcholine molecular species in BAL fluid and lung tissue was unchanged in 1HGU/m1HGU mice compared with controls. The increase in phospholipids in BAL fluid of cftr(m1HGU/m1HGU) mice resulted from an increased fraction of large aggregates which exhibited normal surface tension function. Conclusion - In cftr(m1HGU/m1HGU) mice surfactant homeostasis is perturbed by an increased phospholipid pool in the alveolar compartment.
AB - Background - Progressive pulmonary dysfunction is a characteristic symptom of cystic fibrosis (CF) and is associated with functional impairment and biochemical alterations of surfactant phospholipids in the airways. However, the fundamental question of whether surfactant alterations in the CF lung are secondary to the pulmonary damage or are present before initiation of chronic infection and inflammation has yet to be resolved in patients with cystic fibrosis but can now be addressed in CF mice that exhibit the basic defect in the airways. A study was therefore undertaken to investigate the pool sizes, composition, and function of lung surfactant in the non-infected cftr(m1HGU/m1HGU) mouse. Methods - The amount and composition of phospholipid classes and phosphatidylcholine molecular species were determined in bronchoalveolar lavage (BAL) fluid and lavaged lungs by high performance liquid chromatography (HPLC). Surfactant protein A (SP-A) levels in BAL fluid were determined by ELISA and surfactant for functional measurements was isolated from BAL fluid by differential ultracentrifugation. Equilibrium and minimal surface tension of surfactant was assessed by the pulsating bubble surfactometer technique. MF1, BALB/c, C57/BL6, and C3H/He mice served as controls. Results - BAL fluid of cftr(m1HGU/m1HGU) mice contained 1.02 (95% confidence interval (CI) 0.89 to 1.16) μmol phospholipid and 259 (239 to 279) ng SP-A. BAL fluid of MF1, BALB/c, C57BL/6, and G3H/He mice contained 0.69 (0.63 to 0.75), 0.50 (0.42 to 0.57), 0.52 (0.40 to 0.64), and 0.45 (0.27 to 0.63) μmol phospholipid, respectively. After correction for the different body weights of mouse strains, phospholipid levels in BAL fluid of cftr(mlHGU/mlHGU) mice were increased by 64 (52 to 76)%, 60 (39 to 89)%, 72 (45 to 113)%, and 92 (49 to 163)%, respectively, compared with controls. The amount of SP-A in BAL fluid and the composition of phospholipid as well as phosphatidylcholine molecular species in BAL fluid and lung tissue was unchanged in 1HGU/m1HGU mice compared with controls. The increase in phospholipids in BAL fluid of cftr(m1HGU/m1HGU) mice resulted from an increased fraction of large aggregates which exhibited normal surface tension function. Conclusion - In cftr(m1HGU/m1HGU) mice surfactant homeostasis is perturbed by an increased phospholipid pool in the alveolar compartment.
UR - http://www.scopus.com/inward/record.url?scp=0030774775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030774775&partnerID=8YFLogxK
U2 - 10.1136/thx.52.8.723
DO - 10.1136/thx.52.8.723
M3 - Article
VL - 52
SP - 723
EP - 730
JO - Thorax
JF - Thorax
SN - 0040-6376
IS - 8
ER -